PROCEPT BioRobotics Corporation
PRCT Healthcare Medical Devices
PROCEPT BioRobotics Corporation’s revenue for fiscal 2025 (year ended December 2025) was $308.1 million, up 37.2% from fiscal 2024. In the quarter to June 2026, revenue grew 19.3%, EPS fell 34.3%, free cash flow fell 24.4% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
Follow PRCT
PROCEPT BioRobotics Corporation (PRCT) EV/Sales
As of 16 October 2026, PROCEPT BioRobotics Corporation (PRCT) trades at a EV/Sales of 2.5×. Over the past ten years it has ranged from 0.0× (September 2021) to 41.4× (June 2022); the current reading is higher than 4% of that period. That is above the Medical Devices industry median of 2.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 4.9× | (71.82%) |
| FY2024 | 17.4× | 35.45% |
| FY2023 | 12.9× | (39.19%) |
| FY2022 | 21.2× | 352.28% |
| FY2021 | 4.7× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 3.3× | (12.90%) |
| Mar 2026 | 3.8× | (22.85%) |
| Dec 2025 | 4.9× | (15.66%) |
| Sep 2025 | 5.8× | (45.57%) |
| 19 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| LMRI Lumexa Imaging Holdings, Inc. compare | 1.0× |
| ENOV Enovis Corporation compare | 1.0× |
| TNDM Tandem Diabetes Care, Inc. compare | 1.2× |
| QDEL QuidelOrtho Corporation compare | 1.4× |
| IART Integra LifeSciences Holdings Corporation compare | 1.6× |
| PRCT PROCEPT BioRobotics Corporation | 2.5× |
| AORT Artivion, Inc. compare | 2.9× |
| CBLL CeriBell, Inc. compare | 8.3× |
| IRMD iRadimed Corporation compare | 12.4× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)